Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 3131

2.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

3.
4.
5.
6.

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

Grover SA, Kaouache M, Joseph L, Barter P, Davignon J.

Arch Intern Med. 2009 Oct 26;169(19):1775-80. doi: 10.1001/archinternmed.2009.328.

PMID:
19858435
7.

Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.

Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.

Eur J Intern Med. 2009 Mar;20(2):197-200. doi: 10.1016/j.ejim.2008.06.009. Epub 2008 Aug 15.

PMID:
19327612
8.

Plasma lipoprotein levels as predictors of cardiovascular death in women.

Bass KM, Newschaffer CJ, Klag MJ, Bush TL.

Arch Intern Med. 1993 Oct 11;153(19):2209-16.

PMID:
8215724
9.

Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study.

Lozano JV, Pallarés V, Cea-Calvo L, Llisterri JL, Fernández-Pérez C, Martí-Canales JC, Aznar J, Gil-Guillén V, Redón J; Investigators of the PREV-ICTUS Study.

Curr Med Res Opin. 2008 Mar;24(3):659-70. doi: 10.1185/030079908X273372. Epub 2008 Jan 23.

PMID:
18218194
11.
12.

Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?

George PB, Tobin KJ, Corpus RA, Devlin WH, O'Neill WW.

Am Heart J. 2001 Nov;142(5):857-63.

PMID:
11685175
13.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
14.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
15.

Risk of cardiovascular events in patients at optimal values for combined lipid parameters.

Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ.

Curr Med Res Opin. 2007 Mar;23(3):553-63.

PMID:
17357251
16.

Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.

Dupuy AM, Carrière I, Scali J, Cristol JP, Ritchie K, Dartigues JF, Gambert P, Ancelin ML.

Climacteric. 2008 Feb;11(1):74-83. doi: 10.1080/13697130701877108.

PMID:
18202967
17.

Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study.

Azizi F, Raiszadeh F, Salehi P, Rahmani M, Emami H, Ghanbarian A, Hajipour R.

Nutr Metab Cardiovasc Dis. 2002 Apr;12(2):80-9.

PMID:
12189907
18.

Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy.

Jafri H, Alsheikh-Ali AA, Karas RH.

J Am Coll Cardiol. 2010 Jun 22;55(25):2846-54. doi: 10.1016/j.jacc.2009.12.069. Review.

19.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
20.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk